Print this page Email this page
Users Online: 286
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 


 
 Table of Contents  
LETTER TO EDITOR
Year : 2021  |  Volume : 35  |  Issue : 1  |  Page : 45

New COVID-19 vaccines and new COVID-19 variants: A long way for COVID-19 containment?


1 Private Academic Practice, Bangkok, Thailand
2 Department of Community Medicine, Dr DY Patil University, Pune, Maharashtra, India

Date of Submission11-Feb-2021
Date of Acceptance17-Apr-2021
Date of Web Publication04-Aug-2021

Correspondence Address:
Rujittika Mungmungpuntipantip
Private Academic Consultant, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jms.jms_31_21

Rights and Permissions

How to cite this article:
Mungmungpuntipantip R, Wiwanitkit V. New COVID-19 vaccines and new COVID-19 variants: A long way for COVID-19 containment?. J Med Soc 2021;35:45

How to cite this URL:
Mungmungpuntipantip R, Wiwanitkit V. New COVID-19 vaccines and new COVID-19 variants: A long way for COVID-19 containment?. J Med Soc [serial online] 2021 [cited 2021 Oct 26];35:45. Available from: https://www.jmedsoc.org/text.asp?2021/35/1/45/323160



Sir,

Coronavirus disease 2019 (COVID-19) has caused major public health issues worldwide for more than a year. The World Health Organization already declared and upgraded the COVID-19 epidemic to a “Public Health Emergency of International Concern.” At present, COVID-19 pandemic is the global problem that is not successfully contained. The newly available COVID-19 vaccines become the new hope for successful COVID-19 containment.[1] Nevertheless, the efficacy and safety of the new vaccines become important issues in global public health. In addition, different new COVID-19 vaccines also express different cost-effectiveness.[2] A more important consideration is the continuous report on the new COVID-19 variants. It is a new issue for discussion regarding the possible vaccine escape due to the new COVID-19 variants.[3]

Regarding the COVID-19 vaccine, the necessary conditions for a suitable antigen include large enough molecular weight, complex structure, stable shape, and metabolic breakdown. Moreover, the antigenic determinant site (epitope) and the binding force between antigen and receptor are also determinants of antigen specificity. Various studies seek to understand the characteristics and variability of the virus as early as possible, hoping to find effective vaccines and medicine. Therefore, it is extremely important to understand the mutant coronavirus strain. Current evidence shows that this mutant virus contains several genetic mutations, which make the virus spread more easily from person to person and increase the infection rate. For example, the mutant coronavirus strain VUI-202012/01 occurred in the UK.[4] The VUI-202012/01 was first observed in the UK and the association with high transmissibility is reported.[4] The important genetic change is mutation N501Y inside the spike glycoprotein's receptor-binding domain, which is an important molecular part binding to the angiotensin-converting enzyme 2 receptor in humans and further causes disease, and can confirm the nature of higher transmissibility of VUI-202012/01. Regarding pathophysiology, the molecular structural change of the antigen might be related to the transmissibility.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Shariare MH, Parvez MA, Karikas GA, Kazi M. The growing complexity of COVID-19 drug and vaccine candidates: Challenges and critical transitions. J Infect Public Health 2021;14:214-20.  Back to cited text no. 1
    
2.
Sookaromdee P, Wiwanitkit V. New COVID-19 vaccines, its cost and shelf life: A cost effectiveness analysis. Reply: Arch Med Res 2021;52:453.  Back to cited text no. 2
    
3.
Wiwanitkit V. COVID-19 Variants, Epitope Change, Vaccine Escape, Booster Doses of New COVID-19 Vaccine. Available from: https://www.bmj.com/content/372/bmj.n232/rr. [Last accessed on 20 Jun 2021].  Back to cited text no. 3
    
4.
Elfiky AA, Ibrahim IM. Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico. Reply: J Infect 2021;82:186-230.  Back to cited text no. 4
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed250    
    Printed4    
    Emailed0    
    PDF Downloaded39    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]